Clinical Trial Update: Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for almonertinib with pemetrexed and carboplatin in EGFR T790M+ advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer Non-small Cell

Drugs mentioned

• Almonertinib (almonertinib)
• CARBOPLATIN (Carboplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Fudan University | Conditions: Lung Cancer, Non-small Cell, EGFR T790M | Phase 2 | Status: UNKNOWN